35 results about "Filamin" patented technology

A composition of phosphodiester oligonucleotides of various defined sizes has been created that mimics the effects of defibrotide. The composition essentially consists of mixtures of synthetic phosphodiester oligonucleotides comprising Nmers ranging from 40 mers to 65 mers. The phosphodiester oligonucleotides are preferably heteropolymers composed of either A, G, C, and T at each position but may also be homopolymers, i.e. the same base may be present at each position in the oligonucicotidc. These mixtures are effective in the treatment of cancer and other diseases.

Methods and compositions for determining whether a subject at least has a neoplastic disease are provided. In practicing the subject methods, a sample from a subject is assayed for a soluble filamin analyte, such as a filamin A analyte, to determine whether the subject at least has the neoplastic disease. Also provided are kits, systems, and devices for practicing the subject methods.

Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including the detection of levels of variety of biomarkers diagnostic of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, and LY9. Additionally, age can be used as a predictor variable. The invention also provides methods of treating prostate cancer which rely on diagnostic information obtained based on the detection of biomarkers of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, LY9, and / or age. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

A composition and method are disclosed that utilize an isolated polypeptide or analog thereof to inhibit the interaction of a mu-opioid receptor with filamin A. A contemplated polypeptide has an amino acid residue sequence illustrated by the formula: W-[X1X2X3 . . . X43X44X45]nValAlaX48GlyLeu[X51X52X53 . . . X94X95X96]m-Y, wherein the various elements are defined elsewhere. A contemplated method can be used to select a VAKGL-binding compound.

Methods and compositions for determining whether a subject at least has a neoplastic disease are provided. In practicing the subject methods, a sample from a subject is assayed for a soluble filamin analyte, such as a filamin A analyte, to determine whether the subject at least has the neoplastic disease. Also provided are kits, systems, and devices for practicing the subject methods.

The invention provides method for diagnosis, monitoring, and prognosis of prostate cancer using one or more of keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, and LY9, and PSA. The invention provides kits for practicing the methods of the invention.

Filamin-B peptides, compositions comprising such peptides, and methods of using such peptides to assess an immune response against such peptides are described. An immune response against the peptides correlates with an immune response, in particular a cellular immune response, against prostate cancer cells which immune response is preferably associated with prophylaxis of prostate cancer, treatment of prostate cancer, and / or amelioration of at least one symptom associated with prostate cancer.

The invention relates to a method for expressing Reteplase (rPA) in Escherichia coli by using a dual plasmid system. The method comprises the following steps of: performing polymerase chain reaction (PCR) amplification to obtain gene segment of the rPA, and cloning the gene segment into a vector pET22b to construct a recombinant plasmid pET22b-rPA; co-transforming the pET22b-rPA and pET40b into Escherichia coli BL21 (DE3) by using different resistances of the pET22b-rPA and the pET40b, and screening engineering bacteria under ampicillin (Amp) and kanamycin (Kan) double resistance selection pressure; and performing inducible expression on the engineering bacteria by using isopropyl-beta-D-1-thiogalactopyranoside (IPTG) to obtain the soluble rPA target protein. Through detection by a fibrin plate method, the rPA protein obtained in the method is not needed to be subjected to renaturation and has obvious thrombolytic activity.

Immunohistochemical methods and compositions for the typing of molecular subgroups of medulloblastomas are provided. The methods comprise determining a protein expression profile for a sample obtained from a medulloblastoma by detecting expression of GAB 1, filamin A, or at least two biomarker proteins selected from the group consisting of β-catenin, YAP1, GAB1, and filamin A, and typing the medulloblastoma as a WNT pathway tumor, a SHH pathway tumor, or a non-WNT / non-SHH tumor based on this protein expression profile. Kits for typing a medulloblastoma according to these three molecular subgroups are provided. The kits comprise at least two antibodies, wherein each of said antibodies specifically binds to a distinct biomarker protein selected from the group consisting of β-catenin, YAP1, GAB1, and filamin A, and can optionally comprise one or more of instructions for use, reagents for detecting antibody binding to one or more of said biomarker proteins, and one or more positive control samples.

The present invention relates to a pharmaceutical composition for preventing or treating a hypertrophic scar. The present inventors acknowledged that expression inhibition of thioredoxin 5, PRRC1, S100A11, galectin 1, filamin A, eukaryotic initiation factor-5A, annexin A2 and fatty acid binding proteins 5 can be a new target for relieving and treating a hypertrophic scar. According to the present invention, the treatability of a hypertrophic scar is confirmed by producing thioredoxin 5-, PRRC1-, S100A11-, galectin 1-, filamin A-, eukaryotic initiation factor-5A-, annexin A2- and FABP5-specific siRNAs. Therefore, the knockdown of the proteins or genes coding same induces cell death in a hypertrophic scar and reduces collagen expression and thus can be highly useful for scar treatment.

The invention discloses a recombinant protein specifically bound with fibrin and the application thereof. The protein is a fusion protein which is obtained by fusing the following polypeptides a) or b) or c) or d) as fusion partners to an amino terminal of a target protein: a) a polypeptide prepared from an amino acid sequence as shown in the 22-107 positions from an amino terminal of sequence 2 in the sequence table; b) the polypeptide prepared from the amino acid sequence as shown in the 22-109 positions from the amino terminal of sequence 4 in sequence table; c) a polypeptide which is derived from a) and is prepared after replacement and / or deletion and / or addition of one or more amino acids from the amino acid sequence restricted by a) and can be specifically bound with fibrin; d) a polypeptide which is derived from b) and is prepared after replacement and / or deletion and / or addition of one or more amino acids from the amino acid sequence restricted by b) and can be specifically bound with fibrin. The recombinant protein specifically bound with fibrin of the invention can be used for wound restoration and active tissue induction regeneration.

The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds.

The invention provides method for diagnosis, monitoring, and prognosis of prostate cancer using one or more of keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, and LY9, and PSA. The invention provides kits for practicing the methods of the invention.

A composition and method are disclosed that utilize an isolated polypeptide or analog thereof to inhibit the interaction of a mu-opioid receptor with filamin A. A contemplated polypeptide has an amino acid residue sequence illustrated by the formula: W—[X1X2X3 . . . X43X44X45]nValAlaX48GlyLeu[X51X52X53 . . . X94X95X96]m—Y wherein the various elements are defined elsewhere. A contemplated method can be used to select a VAKGL-binding compound.

The present invention is directed to a method of detecting intact fibrinogen, comprising the steps of: a) providing a sample containing at least some fibrinogen optionally converted at least in part to fibrin, and optionally containing thrombin; b) solubilizing the sample in a solubilizing solution that inhibits thrombin activity; c) after optional SDS-PAGE transferring / applying a portion of said sample to a protein-binding membrane; d) reacting the fibrinogen with a primary monoclonal antibody capable of binding to fibrinopeptide A moiety; and e) detecting the quantity of intact fibrinogen in the sample by quantifying the amount of the bound primary monoclonal antibody.

The present invention relates to a method of diagnosing acute pulmonary embolism (PE) in a subject including a) determining the amount of fibrin-fibrinogen degradation products, in particular D-dimer in a sample of the subject; b) determining the amount of a natriuretic peptide in a sample of the subject; c) determining the amount of a cardiac troponin in a sample of the subject; and d) comparing the amounts determined in steps a) to c) to reference amounts, thereby establishing the diagnosis. Included is also a method of deciding on a therapy of a subject diagnosed with PE and a method of monitoring the therapy.

Compounds represented by formula (I) belowand pharmacologically acceptable salts thereof and solvates of them; pharmaceutical compositions and dynamin-related protein 1 (Drp1)-filamin complex formation inhibitors containing them; and uses of the compounds, salts, solvates, pharmaceutical compositions, and (Drp1)-filamin complex formation inhibitors for use as a prophylactic or therapeutic agent.

In joint reconstruction, repair and cushioning applications, a synthetic polypeptide material is useful that contains cross-linked polypeptides that are modeled on human elastin or other fibrous proteins. The polypeptides comprise at least three consecutive beta-sheet / beta-turn structures and at least one amino acid residue that participates in cross-linking.

The disclosure teaches antibodies that are useful, inter alia, in methods for detecting and treating human cancer. In a particular aspect, the disclosure teaches novel antibodies that are useful for detecting and treating human breast cancer. In some embodiments, the disclosure teaches novel antibodies that bind to filamin A. In some embodiments, the antibodies are intrabodies.

The invention discloses a sipunculus nudus plasmin cDNA gene, a recombined plasmin and applications of the recombined plasmin and belongs to the technical field of genetic engineering. The sipunculus nudus plasmin cDNA gene sequence and the amino acid sequence thereof are shown as SEQ ID NO:1 and SEQ ID NO:2. The cDNA sequence encodes 834 nucleotides, namely 277 amino acids. Through a pGAPZaA vector, the sipunculus nudus plasmin cDNA gene is transferred into a pichia pastoris GS115 strain to perform secretory expression. The recombined plasmin can directly dissolve fibrin in thrombi, and can be used for preparing thrombolytic medicines to treat thrombotic diseases.

The present invention provides a compound of Formula I, and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.

The present invention encompasses filamin B (FLNB) binding proteins. Specifically, the invention relates to antibodies to FLNB. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention in methods of diagnosis, monitoring and prognosis or prostate cancer are also provided.

Immunohistochemical methods and compositions for the typing of molecular subgroups of medulloblastomas are provided. The methods comprise determining a protein expression profile for a sample obtained from a medulloblastoma by detecting expression of GAB1, filamin A, or at least two biomarker proteins selected from the group consisting of β-catenin, YAP1, GAB1, and filamin A, and typing the medulloblastoma as a WNT pathway tumor, a SHH pathway tumor, or a non-WNT / non-SHH tumor based on this protein expression profile. Kits for typing a medulloblastoma according to these three molecular subgroups are provided. The kits comprise at least two antibodies, wherein each of said antibodies specifically binds to a distinct biomarker protein selected from the group consisting of β-catenin, YAP1, GAB1, and filamin A, and can optionally comprise one or more of instructions for use, reagents for detecting antibody binding to one or more of said biomarker proteins, and one or more positive control samples.

A cell communication network factor 5 (CCN5, alias WISP2, CTGFL, CT58) is a member of a stromal cell protein CCN family, and is expressed in various cells and other tissue cells constituting a blood vessel. It is proved in the patent that vascular endothelium and smooth muscle cells CCN5 play different roles in injured angiogenesis intimal hyperplasia, endothelial cells CCN5 can promote injured endothelial cell repair to inhibit intimal hyperplasia by combining an integrin signal path and other mechanisms, and can also inhibit neogenesis intimal hyperplasia by regulating the function of smoothmuscle cells through paracrine; the smooth muscle CCN5 can regulate and control the functions of vascular smooth muscle cells through Filamin A or Thymosin beta 4 or other mechanisms to inhibit neogenesis intimal hyperplasia; and in addition, the recombinant CCN5 protein can also inhibit platelet aggregation. The invention provides application of a CCN5 gene, CCN5 protein, CCN5 active polypeptideor an accelerant thereof, and the CCN5 gene, CCN5 protein, CCN5 active polypeptide or the accelerant thereof are used for preparing a composition or a preparation, and the composition or the preparation is used for treating cardiovascular diseases such as vascular restenosis after coronary heart disease interventional therapy.